Marc Gurwith

9.5k total citations · 2 hit papers
121 papers, 6.7k citations indexed

About

Marc Gurwith is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Marc Gurwith has authored 121 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Infectious Diseases, 46 papers in Epidemiology and 28 papers in Virology. Recurrent topics in Marc Gurwith's work include HIV Research and Treatment (20 papers), SARS-CoV-2 and COVID-19 Research (16 papers) and Escherichia coli research studies (14 papers). Marc Gurwith is often cited by papers focused on HIV Research and Treatment (20 papers), SARS-CoV-2 and COVID-19 Research (16 papers) and Escherichia coli research studies (14 papers). Marc Gurwith collaborates with scholars based in United States, Canada and Germany. Marc Gurwith's co-authors include Andrew B. Onderdonk, Sherwood L. Gorbach, John G. Bartlett, T.-W. Chang, James Brunton, Peter B. Gilbert, William L. Heyward, Allan Ronald, G. K. M. Harding and Shana Feltham and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Marc Gurwith

118 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antibiotic-Associated Pseudomembranous Colitis Due to Toxin-Producing Clostridia

1978 1.0k citations Marc Gurwith et al. profile →
Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

2006 569 citations Punnee Pitisuttithum, Marc Gurwith et al. profile →

Peers

Countries citing papers authored by Marc Gurwith

Since Specialization

Citations

This map shows the geographic impact of Marc Gurwith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Gurwith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Gurwith more than expected).

Fields of papers citing papers by Marc Gurwith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Gurwith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Gurwith. The network helps show where Marc Gurwith may publish in the future.

Co-authorship network of co-authors of Marc Gurwith

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Gurwith. A scholar is included among the top collaborators of Marc Gurwith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Gurwith. Marc Gurwith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine 2024 ·Vaccine ·Shanti Pather, (unknown), (unknown), (unknown), Andrew Finlayson, (unknown), Alexander Muik, Claudia Lindemann, (unknown), Sultan Abdul-Jawad, Emily Smith, Marc Gurwith, Robert T. Chen	1
2	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine 2023 ·Vaccine ·(unknown), Luke Tzu-Chi Liu, Chia-En Lien, Emily Smith, Marc Gurwith, Robert T. Chen	3
3	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus 2022 ·Vaccine ·(unknown), (unknown), Sushant Sahastrabuddhe, Jean‐Louis Excler, Sonali Kochhar, Emily Smith, Marc Gurwith, Robert T. Chen	5
4	The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety 2021 ·Vaccine ·Steven Black, Barbara Law, Robert T. Chen, Cornelia L. Dekker, Miriam Sturkenboom, Wan‐Ting Huang, Marc Gurwith, G. A. Poland	41
5	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines 2020 ·Vaccine ·Richard Condit, (unknown), James S. Robertson, Jean‐Louis Excler, Marc Gurwith, Thomas P. Monath, George N. Pavlakis, Patricia Fast, Jonathan Smith, Emily Smith, Robert T. Chen, Sonali Kochhar	5
6	Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines 2018 ·Vaccine ·Sonali Kochhar, Jean‐Louis Excler, Karin Bok, Marc Gurwith, Michael M. McNeil, Stephen Seligman, Najwa Khuri‐Bulos, (unknown), (unknown), James S. Robertson, Vidisha Singh, Robert T. Chen	15
7	Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains 2016 ·Vaccine ·Richard Condit, Anna‐Lise Williamson, Rebecca Sheets, Stephen Seligman, Thomas P. Monath, Jean‐Louis Excler, Marc Gurwith, Karin Bok, James S. Robertson, (unknown), R. Michael Hendry, Vidisha Singh, (unknown), Robert T. Chen	32
8	Oral Priming with Replicating Adenovirus Serotype 4 Followed by Subunit H5N1 Vaccine Boost Promotes Antibody Affinity Maturation and Expands H5N1 Cross-Clade Neutralization 2015 ·PLoS ONE ·Surender Khurana, Elizabeth M. Coyle, Jody Manischewitz, Lisa R. King, Glenn Ishioka, Jeff Alexander, Jon Smith, Marc Gurwith, Hana Golding	17
9	Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C 2013 ·PLoS ONE ·Jeff Alexander, Jason Mendy, Lo Vang, Jenny B. Avanzini, Fermin Garduño, Darly J. Manayani, Glenn Ishioka, Peggy Farness, (unknown), Ronald Swanstrom, Robert Parks, Hua-Xin Liao, Barton F. Haynes, David C. Montefiori, Celia C. LaBranche, Jonathan D. Smith, Marc Gurwith, (unknown)	18
10	Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999–2003 2010 ·International Journal of Drug Policy ·Michael Martin, Suphak Vanichseni, Pravan Suntharasamai, Philip A. Mock, Frits van Griensven, Punnee Pitisuttithum, Jordan W. Tappero, Sithisat Chiamwongpaet, Udomsak Sangkum, Dwip Kitayaporn, Marc Gurwith, Kachit Choopanya	30
11	Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999–2003 2009 ·Addiction ·Pravan Suntharasamai, Michael Martin, Suphak Vanichseni, Frits van Griensven, Philip A. Mock, Punnee Pitisuttithum, Jordan W. Tappero, Udomsak Sangkum, Dwip Kitayaporn, Marc Gurwith, Kachit Choopanya	26
12	Comparison of HIV Type 1 Incidence Observed during Longitudinal Follow-Up with Incidence Estimated by Cross-Sectional Analysis Using the BED Capture Enzyme Immunoassay 2006 ·AIDS Research and Human Retroviruses ·J. Steven McDougal, Bharat Parekh, Michael Peterson, Bernard M. Branson, Trudy Dobbs, Marta Ackers, Marc Gurwith	119
13	HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers 2006 ·AIDS ·Elizabeth J. McFarland, Daniel Johnson, Petronella Muresan, Terence Fenton, Georgia D. Tomaras, James McNamara, Jennifer S. Read, Steven D. Douglas, Jaime G. Deville, Marc Gurwith, Sanjay Gurunathan, John S. Lambert	41
14	LC16m8: An attenuated smallpox vaccine 2006 ·Vaccine ·Julie Kenner, Fiona Cameron, Cyril Empig, David V. Jobes, Marc Gurwith	129
15	Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial 2006 ·Vaccine ·Geoffrey J. Gorse, W Keitel, Harry Keyserling, (unknown), Michael Lock, (unknown), Julie Kenner, (unknown), Marc Gurwith	83
16	Motivations for Participating in an HIV Vaccine Efficacy Trial 2005 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Grant Colfax, Susan Buchbinder, (unknown), Connie Celum, David J. McKirnan, Judith L. Neidig, Beryl A. Koblin, Marc Gurwith, Brad Bartholow	69
17	Differential efficacy in prevention of HIV infection by rgp120 HIV-1 vaccine by gender and race Is it real? 2003 ·(unknown), Marc Gurwith, D. P. Francis, Clayton Harro, Kenneth H. Mayer, William L. Heyward, Phillip W. Berman, (unknown)	1
18	Clinical Efficacy of Amphotericin B Colloidal Dispersion against Infections Caused by <i>Aspergillus</i> spp 1999 ·Chemotherapy ·Marc Gurwith	9
19	Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. 1997 ·PubMed ·Mary H. White, E. Anaissie, Shimon Kusne, John R. Wingard, J. Hiemenz, Alan Cantor, Marc Gurwith, Charles Du Mond, Richard D. Mamelok, Raleigh A. Bowden	133
20	Prolonged outbreak of nosocomial urinary tract infection with a single strain of Pseudomonas aeruginosa. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Thomas J. Marrie, (unknown), Marc Gurwith, Allan Ronald, G. K. M. Harding, Graeme N. Forrest, W. C. Forsythe	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact